Breast Cancer

Carey Anders, MD, discusses the scenario of a 34-year-old patient diagnosed with HER2-positive breast cancer, who develops brain metastases after undergoing initial therapy with dual HER2 blockade.

Heather Moore, CPP, PharmD, presents a comprehensive summary of targeted therapies for HER2-positive breast cancer and provides expert insights into the management of adverse effects associated with these treatments.

Virginia Kaklamani, MD, offers clinical insights on treatment toxicity considerations in HR+ breast cancer, and the Oncology Brothers outline key takeaways from the discussion.

Medical oncologists provide comprehensive insights on the standard-of-care treatment practices for patients with advanced/metastatic HR+ breast cancer.

The Oncology Brothers and Virginia Kaklamani, MD, outline the treatment algorithm for patients with locally advanced HR+ breast cancer.

Virginia Kaklamani, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss treatment paradigms for patients with early-stage HR+ breast cancer, highlighting the differences in treatment for premenopausal and postmenopausal patients.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Susan Dent, MD, delves into treatment approaches for triple-positive breast cancer in the second-line and beyond, highlighting findings from the DESTINY-Breast03 trial.

Carey Anders, MD, and Susan Dent, MD, discuss the role of radiotherapy in patients with HER2-positive breast cancer and brain metastases.

Treatment with second-line vepdegestrant in those with advanced breast cancer is currently under evaluation as part of the phase 3 VERITAC-2 trial.

Screening frequency appears to be a weak risk factor for advanced breast cancer, with obesity in post-menopausal and dense breasts in pre-menopausal patients being more prominent factors.

Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.

Medical oncologists discuss the various treatment options for patients with metastatic HER2+ breast cancer and where they fit into the treatment algorithm.

The Oncology Brothers and Harold J. Burstein, MD, PhD, discuss clinical approaches to treating patients with locally advanced HER2+ breast cancer.

Harold J. Burstein, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to provide clinical insights on treatment practices for patients with early-stage HER2+ breast cancer.

High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.

A panel of medical oncologists provides insights on managing toxicities in patients with triple-negative breast cancer who are receiving antibody-drug conjugates.

Ruth M. O’Regan, MD, and Anna Weiss, MD, discuss treatment paradigms for patients with metastatic triple-negative breast cancer and the role of surgery.

The expert panel provides clinical insights on treating patients with high-risk or locally advanced triple-negative breast cancer.

Ruth M. O'Regan, MD, and Anna Weiss, MD, join the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of early-stage node-negative triple-negative breast cancer (TNBC).

Data from a case control study highlight a decrease in the risk of breast cancer among those with increasing sex hormone binding globulin concentrations.

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.

Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.

The FDA has set a Prescription Drug User Fee Act date of June 29, 2024 for SH-105 as a treatment for patients with ovarian cancer or breast cancer.